A citation-based method for searching scientific literature

Renaud Sabatier, Elise Lavit, Jessica Moretta, Eric Lambaudie, Tetsuro Noguchi, François Eisinger, Elisabeth Cherau, Magali Provansal, Doriane Livon, Laetitia Rabayrol, Cornel Popovici, Emmanuelle Charaffe-Jauffret, Hagay Sobol, Patrice Viens. Fam Cancer 2016
Times Cited: 4







List of co-cited articles
29 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Da Yang, Sofia Khan, Yan Sun, Kenneth Hess, Ilya Shmulevich, Anil K Sood, Wei Zhang. JAMA 2011
355
100


Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.
Francisco J Candido-dos-Reis, Honglin Song, Ellen L Goode, Julie M Cunningham, Brooke L Fridley, Melissa C Larson, Kathryn Alsop, Ed Dicks, Patricia Harrington, Susan J Ramus,[...]. Clin Cancer Res 2015
94
75

Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
Joanne Kotsopoulos, Barry Rosen, Isabel Fan, Joel Moody, John R McLaughlin, Harvey Risch, Taymaa May, Ping Sun, Steven A Narod. Gynecol Oncol 2016
56
75


BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
696
75

Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
105
75


BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Philipp Harter, Toby Johnson, Dominique Berton-Rigaud, Sang-Yoon Park, Michael Friedlander, Josep M Del Campo, Muneaki Shimada, Frédéric Forget, Mansoor R Mirza, Nicoletta Colombo,[...]. Gynecol Oncol 2016
34
75

Improved survival in women with BRCA-associated ovarian carcinoma.
Ilana Cass, Rae Lynn Baldwin, Taz Varkey, Roxana Moslehi, Steven A Narod, Beth Y Karlan. Cancer 2003
340
50

BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Rebecca Byler Dann, Julie A DeLoia, Kirsten M Timms, Kristin K Zorn, Jennifer Potter, Darl D Flake, Jerry S Lanchbury, Thomas C Krivak. Gynecol Oncol 2012
75
50

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
J M Cunningham, M S Cicek, N B Larson, J Davila, C Wang, M C Larson, H Song, E M Dicks, P Harrington, M Wick,[...]. Sci Rep 2014
80
50

Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Richard E Buller, Mark S Shahin, John P Geisler, Melanie Zogg, Barry R De Young, Charles S Davis. Clin Cancer Res 2002
42
50

Survival analysis in familial ovarian cancer, a case control study.
R P Zweemer, R H Verheijen, J W Coebergh, I J Jacobs, P J van Diest, J J Gille, S Skates, F H Menko, L P Ten Kate, P Kenemans. Eur J Obstet Gynecol Reprod Biol 2001
20
50

Clinicopathologic features of BRCA-linked and sporadic ovarian cancer.
J Boyd, Y Sonoda, M G Federici, F Bogomolniy, E Rhei, D L Maresco, P E Saigo, L A Almadrones, R R Barakat, C L Brown,[...]. JAMA 2000
380
50

Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Angela Chetrit, Galit Hirsh-Yechezkel, Yehuda Ben-David, Flora Lubin, Eitan Friedman, Siegal Sadetzki. J Clin Oncol 2008
226
50

"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.
David S P Tan, Christian Rothermundt, Karen Thomas, Elizabeth Bancroft, Rosalind Eeles, Susan Shanley, Audrey Ardern-Jones, Andrew Norman, Stanley B Kaye, Martin E Gore. J Clin Oncol 2008
328
50

BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Rohini Roy, Jarin Chun, Simon N Powell. Nat Rev Cancer 2011
726
50

Effect of BRCA mutations on the length of survival in epithelial ovarian tumors.
Y Ben David, A Chetrit, G Hirsh-Yechezkel, E Friedman, B D Beck, U Beller, G Ben-Baruch, A Fishman, H Levavi, F Lubin,[...]. J Clin Oncol 2002
149
50

Improved survival in BRCA2 carriers with ovarian cancer.
Tuya Pal, Jenny Permuth-Wey, Rachna Kapoor, Alan Cantor, Rebecca Sutphen. Fam Cancer 2007
49
50

Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
S J Ramus, A Fishman, P D Pharoah, S Yarkoni, M Altaras, B A Ponder. Eur J Surg Oncol 2001
38
50

Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity.
D J Gallagher, J A Konner, K M Bell-McGuinn, J Bhatia, P Sabbatini, C A Aghajanian, K Offit, R R Barakat, D R Spriggs, N D Kauff. Ann Oncol 2011
73
50

Clinical features of ovarian cancer in Japanese women with germ-line mutations of BRCA1.
H Aida, K Takakuwa, H Nagata, I Tsuneki, M Takano, S Tsuji, T Takahashi, T Sonoda, M Hatae, K Takahashi,[...]. Clin Cancer Res 1998
79
50

BRCA1/2 mutation status is an independent factor of improved survival for advanced (stage III-IV) ovarian cancer.
Vilius Rudaitis, Tadas Zvirblis, Daiva Kanopiene, Dovile Janulynaite, Laimonas Griskevicius, Ramunas Janavicius. Int J Gynecol Cancer 2014
16
50

Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
Robin A Lacour, Shannon N Westin, Larissa A Meyer, Shana N Wingo, John O Schorge, Rebecca Brooks, David Mutch, Ashley Molina, Rebecca Sutphen, Mack Barnes,[...]. Gynecol Oncol 2011
25
50

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, Alexander Gutin, Larissa A Meyer, Darl D Flake, Victor Abkevich, Jennifer Potter, Dmitry Pruss, Pat Glenn,[...]. J Clin Oncol 2010
247
50

Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
Agnieszka Synowiec, Gabriel Wcisło, Lubomir Bodnar, Bohdan Górski, Jolanta Szenajch, Katarzyna Szarlej-Wcisło, Cezary Szczylik. Hered Cancer Clin Pract 2016
9
50

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
S C Rubin, I Benjamin, K Behbakht, H Takahashi, M A Morgan, V A LiVolsi, A Berchuck, M G Muto, J E Garber, B L Weber,[...]. N Engl J Med 1996
343
50


Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
Ewa J Majdak, Geertruida H De Bock, Izabela Brozek, Magdalena Perkowska, Karolina Ochman, Jaroslaw Debniak, Tomasz Milczek, Cees J Cornelisse, J Jassem, Janusz Emerich,[...]. Eur J Cancer 2005
19
25

Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.
John R McLaughlin, Barry Rosen, Joel Moody, Tuya Pal, Isabel Fan, Patricia A Shaw, Harvey A Risch, Thomas A Sellers, Ping Sun, Steven A Narod. J Natl Cancer Inst 2013
95
25

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
498
25

Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3.
Carole Beck, Isabelle Robert, Bernardo Reina-San-Martin, Valérie Schreiber, Françoise Dantzer. Exp Cell Res 2014
174
25

Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
David M Hyman, Qin Zhou, Alexia Iasonos, Rachel N Grisham, Angela G Arnold, Mary F Phillips, Jasmine Bhatia, Douglas A Levine, Carol Aghajanian, Kenneth Offit,[...]. Cancer 2012
59
25

DNA double-strand break repair pathway choice and cancer.
Tomas Aparicio, Richard Baer, Jean Gautier. DNA Repair (Amst) 2014
168
25

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
25

Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
Ping Chen, Kaisa Huhtinen, Katja Kaipio, Piia Mikkonen, Viljami Aittomäki, Rony Lindell, Johanna Hynninen, Annika Auranen, Seija Grénman, Rainer Lehtonen,[...]. Cancer Res 2015
23
25


Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.
Tara M Friebel, Susan M Domchek, Timothy R Rebbeck. J Natl Cancer Inst 2014
115
25

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
509
25

BRCA mutations and outcome in epithelial ovarian cancer (EOC): experience in ethnically diverse groups.
T Safra, W C Lai, L Borgato, M O Nicoletto, T Berman, E Reich, M Alvear, I Haviv, F M Muggia. Ann Oncol 2013
17
25

BRCA-associated ovarian cancer: from molecular genetics to risk management.
Giulia Girolimetti, Anna Myriam Perrone, Donatella Santini, Elena Barbieri, Flora Guerra, Simona Ferrari, Claudio Zamagni, Pierandrea De Iaco, Giuseppe Gasparre, Daniela Turchetti. Biomed Res Int 2014
33
25

Bias in meta-analysis detected by a simple, graphical test.
M Egger, G Davey Smith, M Schneider, C Minder. BMJ 1997
25



Meta-analysis in clinical trials.
R DerSimonian, N Laird. Control Clin Trials 1986
25

Role of BRCA2 in control of the RAD51 recombination and DNA repair protein.
A A Davies, J Y Masson, M J McIlwraith, A Z Stasiak, A Stasiak, A R Venkitaraman, S C West. Mol Cell 2001
503
25

Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
David M Hyman, Qin Zhou, Angela G Arnold, Rachel N Grisham, Alexia Iasonos, Noah D Kauff, David Spriggs. Gynecol Oncol 2011
9
25

Aggregate data meta-analysis with time-to-event outcomes.
Paula R Williamson, Catrin Tudur Smith, Jane L Hutton, Anthony G Marson. Stat Med 2002
387
25

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
M William Audeh, James Carmichael, Richard T Penson, Michael Friedlander, Bethan Powell, Katherine M Bell-McGuinn, Clare Scott, Jeffrey N Weitzel, Ana Oaknin, Niklas Loman,[...]. Lancet 2010
952
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.